Propranolol and Pembrolizumab in Advanced Soft Tissue Sarcoma Patients

The goal of this phase 2 clinical trial is to test efficacy and tolerability of combining propranolol and pembrolizumab in patients with advanced angiosarcoma or undifferentiated pleomorphic sarcoma. The main questions aims to answer: * Primary: determine the progression-free survival rate (PFSR) at 3 months Secondary: determine the objective response rate (ORR), duration of Response (DOR), Progression Free Survival (PFS), Overall Survival (OS). Ensure the safety and tolerability, Determine Quality of Life (QoL) • Exploratory: Characterize the TME Participants will be asked to ensure * Ba

Trial Details

NCT ID
NCT05961761
Phase
PHASE2
Sponsor
Niels Junker
Status
RECRUITING
Cancer Type
Sarcoma
Interventions
  • Propranolol
  • Pembrolizumab
Locations (sample)
  • Aarhus, Denmark|56.15674,10.21076
  • Herlev, Denmark|55.72366,12.43998
  • Oslo, Norway|59.91273,10.74609
  • Stockholm, Sweden|59.32938,18.06871

Key Eligibility Criteria

  • Subjects must have signed and dated an IRB/IEC approved written informed consent form in accordance with regulatory and institutional guidelines. T…
  • Subjects must be willing and able to comply with scheduled visits, treatment schedule, laboratory testing, and other requirements of the study
  • Histologically confirmed diagnosis of unresectable locally advanced or metastatic Angiosarcoma or Undifferentiated Pleomorphic Sarcoma, who has pro…
  • Age ≥18 years

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Sarcoma Trials on Trialify →